Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5944
    +0.0007 (+0.11%)
     
  • NZD/EUR

    0.5547
    +0.0001 (+0.03%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.91
    +0.10 (+0.12%)
     
  • GOLD

    2,325.40
    -13.00 (-0.56%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,295.93
    +94.66 (+0.55%)
     
  • NIKKEI 225

    37,702.95
    -757.13 (-1.97%)
     
  • NZD/JPY

    92.4010
    +0.2860 (+0.31%)
     

Blackstone (BX) Closes Clarus Buyout, Expands in Healthcare

The Blackstone Group L.P. (BX) closes acquisition of Clarus, a global life sciences investment firm, announced in October 2018.

Recently, The Blackstone Group L.P. BX completed the acquisition of global life sciences investment firm, Clarus, ramping up investments in the healthcare sector. The new business will be named as Blackstone Life Sciences, while historical funds will retain the Clarus name.

Notably, Blackstone, being the second largest owner of life sciences office space in the world, has already invested more than $19 billion in healthcare and healthcare-related transactions.

Clarus, in partnership with various biopharmaceutical companies, primarily funds growth-stage investments. With offices in Boston and San Francisco, and experience of investing in more than 50 companies in biopharmaceutical, medical device and diagnostic sectors, Clarus has raised nearly $2.6 billion since inception.

With the acquisition of Clarus, Blackstone, which already manages alternative asset classes like private equity and real estate, has launched Blackstone Life Sciences Investment Platform. Through this private investment platform, the asset manager will be able to invest across various companies and products within the life sciences sector.

The main motive behind this deal is to provide necessary funding to the healthcare industry. While this industry is experiencing extraordinary growth, it lacks proper funds to advance breakthrough healthcare products to the market for addressing medical needs.

Notably, Blackstone’s inorganic growth efforts remain impressive. Moreover, the company is expected to benefit from diversified product and revenue mix. Further, its robust fund-raising ability should support profitability.

The company’s shares have gained 3.8% in the past six months against 17.3% decline recorded by the industry.

The stock currently carries a Zacks Rank #3 (Hold).

Key Picks

Greenhill & Co., Inc. GHL has been witnessing upward estimate revisions for the past 60 days. Moreover, this Zacks #1 Ranked (Strong Buy) stock has rallied more than 20% year to date. You can see the complete list of today’s Zacks #1 Rank stocks here.

TD Ameritrade Holding Corporation AMTD has been witnessing upward estimate revisions for the past 60 days. In addition, the company’s shares have gained 5.2% year to date. At present, it carries a Zacks Rank of 2 (Buy).

Great Southern Bancorp, Inc. GSBC has been witnessing upward estimate revisions for the past 60 days. Additionally, the stock has jumped around 5.1% year to date. It currently holds a Zacks Rank #2.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
TD Ameritrade Holding Corporation (AMTD) : Free Stock Analysis Report
 
Greenhill & Co., Inc. (GHL) : Free Stock Analysis Report
 
The Blackstone Group L.P. (BX) : Free Stock Analysis Report
 
Great Southern Bancorp, Inc. (GSBC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research